Opioid addiction, also known as opioid use disorder (OUD), is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines are developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities.
1Katz, J. (2017, June 05). Drug Deaths in America Are Rising Faster Than Ever. Retrieved December 17, 2018, from https://www.nytimes.com/interactive/2017/06/05/upshot/opioid-epidemic-drug-overdose-deaths-are-rising-faster-than-ever.html?module=inline
The next generation proprietary FluidCrystal® Injection Depot Technology used in the subcutaneous injection of CAM2038 includes a lipid-based liquid with a dissolved active ingredient. Upon injection and contact with fluids in the tissue, the lipid solution transforms into a liquid crystalline gel, which encapsulates the active ingredient, allowing for a slow release of the drug over time.
Everything we think, say and do is with our patients in mind.
We develop next generation therapies for opioid use disorder treatment.
We are proud to be part of the solution.
Braeburn strives to foster high performing teams that are passionate about being on the front lines of addressing the opioid crisis. We work smarter by leveraging technology and fostering a collaborative environment that encourages individuals to share their talents and voices to bring ideas to life.